No Data
Apeloa PharmaceuticalLtd (SZSE:000739) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
Apeloa Pharmaceutical Gets Drug Registration for Influenza Treatment
Apeloa Pharmaceutical (000739.SZ): Kangyu Pharmaceutical has received the pharmaceutical registration certificate for oseltamivir phosphate capsules.
On December 9th, apeloa pharmaceutical (000739.SZ) announced that recently, its wholly-owned subsidiary Zhejiang Puluokangyu Pharmaceutical Co., Ltd. (referred to as "Kangyu Pharmaceutical") received the "Drug Registration Certificate" for oseltamivir phosphate capsules issued by the National Medical Products Administration. Oseltamivir phosphate capsules are used for the treatment of type A and type B influenza in adults and children aged 1 year and older. Patients should use it within 48 hours of the first appearance of symptoms; it is also used for the prevention of type A and type B influenza in adults and adolescents aged 13 years and older. According to relevant data, Oseltamivir phosphate capsules 2
Apeloa Pharmaceutical Signs Strategic Cooperation Framework Deal; Shares Up 3%
Apeloa Pharmaceutical (000739.SZ): signed a global strategy cooperation framework agreement with Jixing Hong Kong.
On November 28th, Gelonhui announced that Apeloa Pharmaceutical (000739.SZ) disclosed that the company ('Party B') and Jixing Pharmaceuticals Hong Kong Limited (referred to as 'Jixing Hong Kong' or 'Party A') recently signed a 'Strategic Cooperation Framework Agreement' based on the principles of equality, mutual benefit, and complementary advantages. The two parties have reached a consensus on the cooperative relationship of the CDMO project, formed a strategic partnership, and will carry out long-term cooperation on the CDMO project.
Apeloa Pharmaceutical Unit Gets China Approval for Bile Flow Injection
Is Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
No Data
